Natco Pharma Q1 net, revenue slump on lower cancer drug sales
Drugmaker Natco Pharma’s June quarter consolidated net profit slumped 57% year-on-year (YoY) to ₹206.5 crore on the back of lower sales of generic cancer drug Lenalidomide. The profit came on a nearly 43% YoY dip in total revenue to ₹794.4 crore, largely attributable to lower sales earnings from Lenalidomide — generic of once blockbuster cancer…
Read More “Natco Pharma Q1 net, revenue slump on lower cancer drug sales” »